Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BELLWAVE-002: Phase 1 nemtabrutinib in Japanese participants with B‑cell malignancies
jRCT2031220583Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of nemtabrutinib in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), Waldenström macroglobulinemia (WM), Lymphoplasmacytic Lymphoma (LPL) and 1 more (2 arms), sponsored by Merck & Co. Primary endpoints: Dose limiting toxicities, Adverse events and 1 more. Started Feb 2023; status: completed.
02
Drugs
nemtabrutinib
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)Waldenström macroglobulinemia (WM)Lymphoplasmacytic Lymphoma (LPL)mature B-cell neoplasm (MBCN)
Beyond the preview
Go deeper on jRCT2031220583.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220583.